Advertisement

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy

  • Jia-Zhen Wu
  • Mustafa Ardah
  • Caroline Haikal
  • Alexander Svanbergsson
  • Meike Diepenbroek
  • Nishant N. Vaikath
  • Wen Li
  • Zhan-You Wang
  • Tiago F. Outeiro
  • Omar M. El-Agnaf
  • Jia-Yi LiEmail author
Open Access
Research
  • 55 Downloads

Abstract

Background

Progressive accumulation of α-synuclein is a key step in the pathological development of Parkinson’s disease. Impaired protein degradation and increased levels of α-synuclein may trigger a pathological aggregation in vitro and in vivo. The chaperone-mediated autophagy (CMA) pathway is involved in the intracellular degradation processes of α-synuclein. Dysfunction of the CMA pathway impairs α-synuclein degradation and causes cytotoxicity.

Results

In the present study, we investigated the effects on the CMA pathway and α-synuclein aggregation using bioactive ingredients (Dihydromyricetin (DHM) and Salvianolic acid B (Sal B)) extracted from natural medicinal plants. In both cell-free and cellular models of α-synuclein aggregation, after administration of DHM and Sal B, we observed significant inhibition of α-synuclein accumulation and aggregation. Cells were co-transfected with a C-terminal modified α-synuclein (SynT) and synphilin-1, and then treated with DHM (10 μM) and Sal B (50 μM) 16 hours after transfection; levels of α-synuclein aggregation decreased significantly (68% for DHM and 75% for Sal B). Concomitantly, we detected increased levels of LAMP-1 (a marker of lysosomal homeostasis) and LAMP-2A (a key marker of CMA). Immunofluorescence analyses showed increased colocalization between LAMP-1 and LAMP-2A with α-synuclein inclusions after treatment with DHM and Sal B. We also found increased levels of LAMP-1 and LAMP-2A both in vitro and in vivo, along with decreased levels of α-synuclein. Moreover, DHM and Sal B treatments exhibited anti-inflammatory activities, preventing astroglia- and microglia-mediated neuroinflammation in BAC-α-syn-GFP transgenic mice.

Conclusions

Our data indicate that DHM and Sal B are effective in modulating α-synuclein accumulation and aggregate formation and augmenting activation of CMA, holding potential for the treatment of Parkinson’s disease.

Keywords

chaperone-mediated autophagy macroautophagy alpha-synuclein protein aggregation Parkinson disease lysosomal-associated membrane protein 

Abbreviations

3-methyladenine

3-MA

ALP

Autophagy-lysosomal pathway

BAC-α-syn-GFP

Bacterial Artificial Chromosome α-synuclein-green fluorescent protein

CMA

Chaperone-mediated autophagy

CQ

Chloroquine

CS

Corpus striatum

DHM

Dihydromyricetin

GFAP

Glial fibrillary acidic protein

HSC/Hsc70

Heat shock (70kDa) protein

Iba1/AIF1

Allograft inflammatory factor 1

IF

Immunofluorescence

IHC

Immunohistochemical

LAMP-1

Lysosomal-associated membrane protein 1

LAMP-2A

Lysosomal-associated membrane protein 2, isoform A

LDH

Lactate dehydrogenase

mTOR

Mammalian target of rapamycin

MTT

3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide

PD

Parkinson’s disease

PVDF

Polyvinylidene difluoride

RT

Room temperature

Sal B

Salvianolic acid B

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

SNpc

Substantia nigra pars compacta

SynT

C-terminal modified α-synuclein

ThS

Thioflavin S

ThT

Thioflavin T

UPS

Ubiquitin-proteasome system

WT α-syn

Wild-type α-synuclein

α-syn/α-Syn

Alpha-synuclein

Background

Aberrant degradation of alpha-synuclein (α-syn) has been implicated in the pathogenesis of Parkinson’s disease (PD) which leads to accumulation of α-syn in Lewy bodies [1, 2]. α-Syn can be selectively translocated into lysosomes for degradation via chaperone-mediated autophagy (CMA), a highly regulated cellular process that mediates the degradation of cytosolic proteins in lysosomes [3, 4, 5, 6]. The protein contains a CMA target motif and is degraded by CMA in neural cells [7, 8]. CMA is controlled by two key CMA regulators: the chaperone HSC70 and the receptor lysosomal-associated membrane protein 2A (LAMP 2A). LAMP-1 is highly structurally homologous to LAMP-2A suggesting that there may be an overlapping function of these two proteins [9, 10]. HSC70 binds to protein substrates containing a KFERQ peptide motif [8, 11]. The substrate–HSC complex interacts with LAMP-1/2A for targeting of identified protein translocation to the lysosome [12, 13, 14, 15]. In addition, the ubiquitin-proteasome system (UPS) and macroautophagy are also involved in α-syn degradation [16, 17, 18].

Several studies have been conducted on the development of small molecular inhibitors of α-syn aggregation for the prevention and treatment of PD [19, 20, 21, 22, 23]. Several important compounds in the daily diet and medicinal plants have been found to be protective against α-syn fibrillation [21, 24]. Dihydromyricetin (DHM), a major active ingredient of flavonoid compounds extracted from the stems and leaves of Ampelopsis grossedentata, has anti-tumor, oxidation resistance and free radical scavenging capabilities [25, 26, 27, 28]. Evidence indicates that DHM has neuroprotective effects by enhancing the formation of autophagosomes and inducing autophagy [29, 30, 31]. Salvianolic acid B (Sal B) is one of the bioactive compounds of Salvia miltiorrhiza Bunge extracted from the root of Salvia miltiorrhiza and has been shown to exert various anti-oxidative and anti-inflammatory effects in both in vitro and in vivo studies [23, 32, 33]. Sal B has recently been associated with preventing fibril aggregation of amyloid proteins and inhibiting neuroinflammation, thereby improving neurological function in animal models of neurodegenerative diseases [23, 24]. However, it is not clear whether DHM and Sal B have any effects on α-syn accumulation and aggregation in synucleinopathies, such as PD.

To further explore the role of CMA mediated degradation of aggregated α-syn and the potential function of autophagy regulated by DHM and Sal B, in the present study, we have investigated the effects of DHM and Sal B on α-syn accumulation and aggregation using both in vitro and in vivo models. We observed that DHM and Sal B upregulated the CMA associated protein LAMP-2A and its homologous protein, LAMP-1, decreased levels of α-syn, reduced cytotoxicity and inhibited inflammatory responses when administered in cell and animal models. Our findings indicate that DHM and Sal B are potential therapeutic compounds that can intervene and halt pathological developments in synucleinopathies.

Methods

Fibril preparation

α-Syn monomers were ordered from Proteos (RP-003) and prepared following the Michael J Fox Foundations guidelines for fibril formation. Briefly, monomeric protein was thawed and spun at 15.000xg for 10 min at 4 °C, to pellet any aggregated materials. The supernatant was then assessed by BCA to determine the α-syn concentration. The monomer sample was diluted to 5 mg/ml in PBS without calcium and magnesium, and transferred to a 1.5 ml Eppendorf tube, then incubated for 7 days in a shaking incubator at 1000 rpm and 37 °C. Final fibril solution was stored at -80 °C in single use aliquots until use.

Inhibitor modulation of α-synuclein aggregation kinetics

Aggregation kinetics were assessed in Corning NBS half-area micro plates(#3881) plates using 70 μM α-syn monomers, 20 μM thioflavin T (Sigma, T3516) and Sal B (Sigma, SML0048, ≥94% (HPLC) ) or DHM (Sigma, SML0295, ≥98% (HPLC) ) at either 15 or 30 μM. Vehicle control wells were set up using a volume equal to that of the highest inhibitor concentration (0,015 μl per well). To initiate the experiment, sonicated α-syn seeds were added to each well at 0.1% of the monomer concentration (70 nM). Kinetics were observed using a BMG FLUOstar Omega plate reader, allowing continual measurements for 7 days at 37 °C. Baseline acquisition was performed for 3 hours before addition of the α-syn seeds, and recordings were continued for 12 hours.

Cell culture and transfection

H4 neuroglioma cells from human (origin) were cultured in Opti-MEM + GlutaMAX (Invitrogen, 51985-034) supplemented with 10% fetal bovine serum (FBS; Gibco, 10100-147) at 37°C, passaged, and plated on chamber slides (Labted-II, Nalgen-Nunc, 154526) or glass cover slips. For intracellular α-syn aggregation experiments, H4 cells were seeded in 24-well plate (5 × 104 cells/well) 24 h prior to transient transfection with SynT (C-terminal tagged form of WT α-syn) and synphilin-1 (Fig. S1). Equi-molar ratios of plasmids were mixed with FuGENE® 6 (Promega, E2691) at a 1:2 mass volume ratio, and incubated for 15 min before the complex of transfection reagent and plasmids was transfected into cells according to the manufacturer’s protocol (2 h transfection and 6 h recovery time). ALP modifiers were incubated during the last 24 h before fixation and processing for immunocytochemistry and toxicity assessments. Co-transfection with an empty backbone-vector [pPAGFP-C1, Addgene, 11910] and mock transfection was used as control. Rapamycin (200 ng/ml, Sigma Aldrich, R0395) was prepared in DMSO, chloroquine diphosphate salt (50 mM, CQ, Sigma Aldrich, C6628) and 3-methyladenine (10 mM, 3-MA, Sigma Aldrich, M9281) in water.

Immunocytochemistry

For drug treatment, 24 h post first transfection with SynT and synphilin-1, cells were further incubated with DHM, Sal B, Rapamycin or Chloroquine. Twenty-four hours later, cells were fixed with 4% PFA for 10 min at room temperature (RT), washed two times with PBS and subjected to immunocytochemistry analysis. Briefly, cells were permeabilized with 0.5% Triton X-100 in PBS for 20 min at RT, blocked for 1 h at RT with 5% normal donkey serum in 0.1% Triton X-100 in PBS, incubated with primary antibody (mouse anti-α-syn 1:1000; BD Biosciences) at 4°C overnight followed by secondary antibody incubation (1:1000, donkey anti-mouse IgG-Alexa568, Jackson ImmunoResearch) for 2 h at RT, then incubated for 10 min with DAPI 1:1000 in PBS (SIGMA-ALDRICH). Specimen analyses were performed with a conventional epifluorescence microscope (Nikon Ni-E). Cells were subjected to microscopy analysis for LAMP-1/-2A and α-syn colocalization using laser-confocal microscope (Leica TCS SP8), followed by analysis using ImageJ software. Sequential multi-track frames were acquired to avoid any potential crosstalk from adjacent fluorophore. For ThS labeling, transfected H4 cells were fixed and incubated prior to IF labeling for 10 min in 0.5 mg/ml thioflavin-S (Sigma, T1892), and washed in 85% absolute ethanol. At least 300 cells from three independent wells were assessed for each experiment and the number of cells containing α-syn positive aggregates were quantified in the transfection conditions by a random sampling survey. The percentage of the transfected cells containing α-syn positive aggregates compared with the total number was then recorded.

Immunohistochemistry of transgenic mice

Six- and nine-month old mice were housed (3-4 animals/cage) with food and water available ad libitum under a 12-h light/dark cycle. All animal experiments followed the Institutional Animal Care and all procedures were performed under the specifications set by the Ethical Committee for Use of laboratory animals at Lund University, Sweden and at Northeastern University, China. Homozygous transgenic mice expressing WT human α-syn fused to green fluorescent protein (GFP), under control of the mouse α-syn promoter show an overexpression of α-syn-GFP in the CS and the dopaminergic neurons of the SNpc. The formation of α-syn aggregates in the brain of transgenic mice has been shown to rise with increasing age [34]. DHM and Sal B (10mg/kg/day for two weeks) were utilized for intra-peritoneal administration of nine-month old mice (n=8 mice per group). Mice were then euthanized 6 weeks later. Brains were removed, post-fixed in 4% PFA and a gradient sucrose sedimentation (10% - 30%) was performed. For mouse brains, 30 micrometer-thick free-floating coronal sections were cut on a freezing microtome (Leica, SM2010R), blocked in solution comprising PBS + 5% horse serum + 0.25% Triton-X 100, and incubated with primary antibodies (mouse-anti-α-syn antibody 1:1000, Santa Cruz Biotechnology, sc-12767; mouse-anti-GFAP antibody 1:1000, MERCK MILLIPORE, MAB360; mouse-anti-Iba1/AIF1 antibody 1:1000, MERCK MILLIPORE, MABN92) overnight in a humid chamber at 4°C. Sections (incubated with anti-α-syn, anti-GFAP and anti-Iba1/AIF1) were then subsequently incubated with secondary biotinylated anti-mouse antibody (Vector Biolabs) followed by DAB staining using the ABC kit (Vector Biolabs) and DAB peroxidase substrate (Vector Biolabs) according to the manufacturer’s protocol. For each animal, 3 sections were analyzed and all sections were processed under the same standardized conditions. α-Syn+, GFAP+ and Iba1+ cells in the CS and SNpc were counted on a Nikon microscope using the NIS-Elements BR imaging system.

Western blot analysis

Cytosolic fractions were obtained by manual homogenization and incubation in ice-cold lysis buffer containing 25 mM TRIS-HCl pH 7.4, EDTA 1 mM, protease inhibitor + 0.1% SDS for 2 h, followed by centrifugation at 12000 rpm for 10 min. In the supernatant, equivalent amounts of LAMP-1/-2A protein sample were loaded and separated by 8% SDS-PAGE gels, and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore) for 2 h at 4°C or overnight at 4°C. Membranes were blocked with 2.5% nonfat milk solution in Tris-buffered saline with 0.1% Triton X-100 (TBST) for 1 h, and then incubated overnight at 4°C with mouse anti-LAMP-1 (Abcam, ab25630, 1:1000), rabbit anti-LAMP-2A (Abcam, ab18528, 1:1000) or mouse anti-β-actin (Sigma, A1978, 1:5000,), followed by HRP-linked secondary antibodies (CST, 7076S for anti-mouse IgG and 7074S for anti-rabbit IgG, 1:10000,) for 2 h at RT. Bands were detected using an ECL detection kit (Cell Signaling Technology) and exposed to X-ray films. Bands were analyzed and normalized to the corresponding β-actin signal for comparison.

Cytotoxicity assays

Cell viability and α-syn cytotoxicity was evaluated by the MTT assay and LDH assay. H4 cells were plated on 96-well plates in complete medium, transfected with SynT and synphilin-1, then co-transfected with a plasmid encoding for WT α-syn, or with empty plasmid. For the MTT assay, 10 μl MTT reagent and 100 μl detergent reagent were added into each well in sequence after incubation for twenty-four hours. The resulting intracellular purple formazan can be solubilized and quantified by spectrophotometric means. For the LDH assay, after twenty-four hours transfection, culture media were collected and used to determine the levels of released Lactate dehydrogenase (LDH). After treatment, assays were performed following the manufacturer’s instructions (Promega, Madison, WI, USA). Results were expressed as the percentage of cell death.

Open Field Assay

Exploratory/locomotor activity of the animals (six-month-old and nine-month-old, n=8 mice per group) was assessed in an open-field paradigm equipped with a video trajectory analysis system (42 × 42 × 36 cm [d × w × h] plexiglass boxes) and analyzed using Smart 3.0 software (Panlab, Span). The mice were first allowed to explore the confined arena for 15 min during each session, then their performance was recorded and ambulatory locomotor activity was measured by offline analysis. Track paths were subsequently analyzed by an automatic system to assess the following parameters: distance traveled (cm), time spent in the various sections of the arena and number of rears.

Data analysis and statistics

Statistical analyses were performed using Prism 6 (GraphPad Software). All data shown are representative from a minimum of three independent experiments unless otherwise stated. Statistical analysis for comparison of groups in the in vitro experiments was performed using the Student’s t-test. For both in vitro and in vivo experiments, statistical significance of difference between groups was determined by the 2-tailed unpaired Student t test of the means. Where values have been compared with the normalized control, a one-sample t test was used. In cases of multiple-group comparisons, a one-way ANOVA was used, with Scheffe’s post hoc test where values have been compared with the control.

Results

Aggregation kinetics of α-synuclein in the presence of Sal B and DHM

We first studied the aggregation kinetics of α-syn in the presence of Sal B and DHM in increasing concentrations using the thioflavin T (ThT) fluorescence assay. ThT can bind to the β-sheet structure of α-syn and changes in the fluorescence signal of this dye are used to monitor the formation of α-syn fibrils. The inhibiting effects of Sal B or DHM on the aggregation kinetics of α-syn were monitored by starting the fibrillation process in the absence and presence of Sal B or DHM while continually measuring the ThT fluorescence from the fibrillation process using the plate-based assays with ThT dye (Fig. 1). Following addition of pre-formed fibrils (PFF) of α-syn, an increase in the ThT fluorescence indicates α-syn conversion from monomer to β-sheet rich aggregates (Fig. 1a, b). The results suggest that Sal B and DHM can effectively inhibit α-syn aggregation in a concentration-dependent manner (10μM and 50 μM for both Sal B and DHM).
Fig. 1

Sal B and DHM inhibit seeded aggregation of α-syn in a concentration dependent manner. Chemical structures of Sal B (a) and DHM (b) as used throughout the study. Seeded α-syn aggregation can be inhibited by addition of either Sal B (a) or DHM (b) in increasing concentrations. A baseline of ThT fluorescence was captured for both A and B for 3 hours. For both Sal B and DHM, a concentration of 1 μM slows the aggregation kinetics, while higher concentrations lead to a complete inhibition of aggregation process. Graphs are plotted as median of 3 replicates (±95% Confidence Interval)

Alterations of CMA markers in an in vitro model of α-synuclein aggregation.

In order to study alterations in α-syn aggregation in vitro, we performed a co-transfection of SynT and synphilin-1 in human neuroglioma cells (H4 cells) for at least 48 h, leading to α-syn aggregation [35] (Additional file 1). As we reported previously, in this aggregation model we detected many large α-syn aggregates in contrast to wild-type (WT) α-syn transfected cells, where diffuse α-syn was present in the cytoplasm (Additional file 1Bi, Ci). In addition, the cells transfected with SynT exhibited large ThS positive aggregates, implying that α-syn aggregates consist of a typical β-sheet conformation in the cells (Additional file 1Bii). Small and diffused α-syn positive structures were also found in each model but were not ThS positive (Additional file 1Cii), in agreement with our previous findings [36].

To further study the effects of DHM and Sal B on α-syn aggregate-degradation in the cells, we used an H4 cell model expressing SynT-aggregation. First, we performed an MTT assay in a dose-dependent manner to optimize the doses of DHM and Sal B. The optimal doses were selected as 10 μM and 50 μM for DHM and Sal B, respectively (Fig. 2a) and the optimal treatment time for both DHM and Sal B was 16 h (data not shown). Morphological analysis of immuno-labeled α-syn-positive structures revealed that larger inclusions (2-5 μm in diameter or larger, Fig.2b) were found in untreated cells than that in DHM or Sal B treated cells (1 μm in mean diameter, Fig. 2c, d and e). Quantitative analysis of CMA marker expression in the SynT-aggregation model by SDS-PAGE and Western blotting revealed that LAMP-1 and LAMP-2A were significantly increased in DHM and Sal B treated cells compared to the cells with empty vector, SynT and WT α-syn transfection (Fig. 3a, b and c), while the expression levels of α-syn were significantly reduced by treatment with DHM and Sal B (Fig. 3a, d). No significant differences for WT α-syn levels were found in any of the cell models except for the SynT-aggregation model (Fig. 3a, d and e). Rapamycin can inhibit the mammalian target of rapamycin (mTOR) pathway and can activate the autophagy-lysosome pathway (ALP) [37]. Chloroquine (CQ) can reduce the fusion of autophagosomes with lysosomes and inhibit the ALP [38]. Therefore, we treated cells expressing SynT with either rapamycin or CQ as positive and negative controls, respectively. We found that the expression pattern of WT α-syn, SynT, LAMP-1 and LAMP-2A were similar in rapamycin treated cells and in DHM and Sal B treated cells. In CQ treated cells, the levels of WT α-syn, LAMP-1 and LAMP-2A were significantly reduced and the levels of SynT were significantly increased as compared to the DHM and Sal B treated cells (p<0.05, Fig. 3). In order to test the involvement of DHM and Sal B in macroautophagy, we treated the SynT-transfected cells with 3-MA as an inhibitor of macroautophagy. The treatment with 3-MA alone resulted in a reduction of LC3-II levels, whereas an increase in expression levels of LC3-II and LAMP-1/2A was observed after DHM or Sal B treatment (Additional file 2). These findings suggest that DHM and Sal B lead to an up-regulation of the LC3-II and LAMP-2A proteins reflecting the involvement of CMA and macroautophagy after treatments with DHM and Sal B.
Fig. 2

The effects of small molecule drugs on α-syn aggregation in H4 cells. (a) MTT assay was performed in a dose-dependent manner in SynT and synphilin 1 co-transfected H4 cells. IF labeling for α-syn (red) showed a greater quantity of large-sized aggregates in untreated cells (b) than that in DHM or Sal B treated cells (c, d, e). All data shown are representatives of at least three independent experiments (mean ± SD, *p<0.05, **p<0.01), Scale bar = 5 μm

Fig. 3

Expression of LAMP-1 and LAMP-2A in α-syn transfected H4 cells. A control group without any transfection was performed as a ‘mock’ while another group with an ordinary wildtype α-syn plasmid transfection was performed as ‘WT α-syn’. SynT and synphilin 1 co-transfected group was performed as the experimental group with DHM, Sal B, Rapamycin or Chloroquine treatments. The expression levels of LAMP-1/-2A, SynT or endogenous α-syn were detected by Western blot (a). Quantitative analyses of α-syn (SynT) and LAMP-1/-2A normalized to β-actin (B-E) (n = 5). Expression of LAMP-1 (b) and LAMP-2A (c) was significantly increased after treatment with DHM or Sal B, as compared with WT α-syn transfected cells, rapamycin treated cells or CQ treated cells (after normalization to untreated cells). (d) SynT levels were decreased in both DHM and Sal B treated cells as compared to the SynT-aggregation model or (CQ) treated cells. (e) WT α-syn expression levels were increased in DHM (10 μM) or Sal B (50 μM) treated cells as compared with the SynT-aggregation model. All data shown are representative of at least three independent experiments (mean ± SD, *p<0.05, **p<0.01)

Next, we examined the effects of DHM and Sal B on α-syn aggregation and the interaction with LAMP-1 and LAMP-2A. Interestingly, we observed that α-syn inclusions co-localized with LAMP-1 and LAMP-2A in more defined regions in cells treated with DHM and Sal B (Fig. 4a, b and d), whereas the untreated cells showed much less co-localization between α-syn and LAMP-1 or LAMP-2A (Fig. 4d), suggesting a potential relationship between the α-syn inclusions and the CMA pathway. Quantification of the signals of α-syn and LAMP-1/-2A revealed that DHM and Sal B treatments increased the levels of LAMP-1/-2A and mitigated α-syn aggregation. Quantification of the mean fluorescence intensity revealed a significant increase of around 60%-70% for LAMP-1 (+75% ± 10.5% SEM for DHM treated group; +58% ± 9.8% SEM for Sal B treated group) and LAMP-2A (+63% ± 10.5% SEM for DHM treated group; +52% ± 8.7% SEM for Sal B treated group) levels in the lysates of SynT-aggregation H4 cells compared to the untreated group (Fig. 4c). The expression level of α-syn was reduced in the DHM and Sal B treated cells (by 77% ± 14.1% SEM for DHM treated group; 68% ± 11.8% SEM for Sal B treated group) compared to the untreated group. Thus, the altered levels of the lysosomal membranes (LAMP-2A) support the association between α-syn aggregation and CMA pathway activation, particularly in response to DHM and Sal B administrations.
Fig. 4

Drug effects on α-syn aggregates and co-localization of LAMP-1, LAMP-2A in the SynT-aggregation model. H4 cells were co-transfected with SynT and synphilin-1. (a-b) Cells were fixed 48 h post-transfection and subjected to IF for α-syn (red) and LAMP-1/-2A (green) followed by confocal microscopic analysis. (c) LAMP-1 and LAMP-2A showed an increased expression level in SynT transfected H4 cells following treatment with DHM (10 μM, 48h) and Sal B (50 μM, 48h), compared to untreated cells. The fluorescence density levels of α-syn were decreased in DHM and Sal B treated cells compared with the control. (d) The co-localization levels of LAMP-1/-2A with α-syn in intracellular aggregates were increased in DHM and Sal B treated cells. All data shown are representative of at least three independent experiments (mean ± SD, *p<0.05, **p<0.01), Scale bar = 5 μm

CMA modulates α-synuclein aggregation and toxicity in vitro

The findings above suggest that CMA modulation may be a potential target for intervention in synucleinopathies. Thus, we investigated whether the effects of α-syn aggregation and toxicity are regulated by CMA (Fig. 5). Although α-syn inclusions were present in approximately 50% of the SynT transfected H4 cells (Fig. 5a, c), the toxicity was not significantly increased compared with that observed in cells expressing WT α-syn (Fig. 5b, d). Both DHM and Sal B treatments decreased the percentage of aggregate-containing cells (SynT transfected H4 cells) from 52.1% (± 10.1% SEM) to 18.2% (± 8.3% SEM, p<0.01, DHM) and 19.6% (± 6.7% SEM, p<0.01, Sal B), respectively, compared with rapamycin treated cells (to 33.8% ± 8.6% SEM, p<0.01) (Fig. 5e). This was paralleled by significant decreases in toxicity by 1.48-fold (± 0.28 SEM, DHM), 1.65-fold (± 0.34 SEM, Sal B) and 1.78-fold (± 0.31 SEM, rapamycin) compared to the SynT transfection model (2.47 fold (± 0.32 SEM)) (Fig. 5f). Thus, these results suggest that DHM and Sal B have ameliorative effects on α-syn aggregation and attenuate toxicity for aggregation-prone α-syn species.
Fig. 5

Molecules modulate the cytotoxicity of α-syn aggregation in cells transfected with WT α-syn or co-transfected with SynT and synphilin-1. Transfection with WT α-syn did not induce clear aggregate formation (green, a), while transfection with SynT leads to distinct α-syn positive inclusions (arrows, B) in 50–60% of transfected cells (c). Nuclei are stained in blue (a and b). (d) Toxicity, as measured by the release of Lactate Dehydrogenase in transfected cells, showed no significant difference between the SynT-aggregation model (n = 6) or WT α-syn control (n = 5). Treatment with DHM or Sal B in SynT transfected cells reduced the number of cells with SynT-inclusions (e, **p<0.01), and ALP activation with rapamycin also showed a decrease in α-syn aggregation in transfected H4 cells (e, *p<0.05). The number of cells with SynT-aggregates was slightly increased after treatment with CQ. (f) Treatments with DHM, Sal B or rapamycin showed a significant decrease in cell toxicity (f, **p<0.01), in contrast to the SynT transfected group, or the CQ treatment group. Scale bar = 5 μm

DHM and Sal B treatments activate CMA pathways and degrade α-syn aggregates in vivo.

To validate the effects of DHM and Sal B treatments in vivo, we administered them to Bacterial Artificial Chromosome (BAC) transgenic mice, expressing WT human α-syn fused to green fluorescent protein (GFP) under the control of the endogenous α-syn promoter [34]. We observed a widespread expression of α-syn-GFP in multiple brain regions, including the corpus striatum (CS) and substantia nigra pars compacta (SNpc). To study the effects of DHM and Sal B on mouse behavior, we assessed locomotor activity in an open field test using 6 and 9-month-old mice. Upon administration of DHM (10 mg/kg/day), Sal B (10 mg/kg/day) or vehicle for two weeks, we did not observe any significant differences in ambulatory movements among the groups of WT vs transgenic mice (treated with DHM, Sal B or vehicle) (Additional file 3). We then examined the expression of α-syn and LAMP-1/-2A in DHM and Sal B treated groups compared to the saline treated group in the BAC-α-syn-GFP transgenic mice. Morphological analyses with IF and immunohistochemical (IHC) preparations revealed that in the CS and SNpc, the levels of α-syn-GFP (IF) (Fig. 6a-d, g-j) and α-syn (IHC) (Fig. 6e, f, k, l) significantly decreased upon administration of DHM and Sal B, while the levels of LAMP-1 (Fig. 6a, b, g, h) and LAMP-2A (Fig. 6c, d, i, j) significantly increased, compared with the saline control group (p<0.05) (Fig. 6a-f, left column), suggesting that DHM (Fig. 6a-f, middle column) and Sal B (Fig. 6A-F, right column) treatments activated CMA pathways in the brains of transgenic mice. Furthermore, we found that LAMP-1, LAMP-2A and α-syn-GFP exhibited a co-localized distribution in some subcellular compartments in the DHM and Sal B treated mice (Additional file 4), further indicating increased degradation of α-syn aggregates via the CMA pathway.
Fig. 6

LAMP-1 and LAMP-2A expression patterns in BAC-α-syn-GFP transgenic mice upon DHM and Sal B treatments. Morphological and quantitative analyses of α-syn-GFP in the CS (a, c) and SNpc (b, d) of BAC-α-syn-GFP transgenic mice showed decreased accumulation of α-syn-GFP, but an increased presence of LAMP-1 and LAMP-2A in DHM/Sal B treated groups compared with the saline treated group (8 animals/group, male). Similar results were observed in immunohistochemcally stained CS (e) and SNpc (f) of BAC-α-syn-GFP transgenic mice treated with DHM/Sal B or with saline control. Quantitative analyses of optical density of α-syn-GFP, LAMP-1 and LAMP-2A are displayed in the right panel (g-j for IF intensity, k and l for the intensity of immunoreactivity). Significant differences are indicated (*p<0.05, **p<0.01) as compared with the saline-treated group. Scale bars = 50 μm

To further explore alterations of α-syn as well as LAMP-1 and LAMP-2A levels in BAC-α-syn-GFP transgenic mice, we performed SDS-PAGE and Western blotting (Fig. 7). We observed that levels of LAMP-1 and LAMP-2A were significantly up-regulated in DHM (Fig. 7a, c) and Sal B treated mice (Fig. 7b, d) in the CS and SNpc compared to the saline treated group, whereas levels of α-syn-GFP were significantly down-regulated following DHM and Sal B treatments. In addition, no changes were observed in the levels of the endogenous mouse α-syn.
Fig. 7

Levels of LAMP-1/-2A, α-syn-GFP and (mouse endogenous) α-syn in BAC-α-syn-GFP transgenic mice. Representative Western blots (a, b) and intensity quantification (c, d) of related proteins normalized to actin are shown (8 animals/group, male). The results show a significant difference between the regions of the CS and SNpc for LAMP-1 and LAMP-2A in DHM (a) and Sal B (b) treated groups and the saline-control group. The levels of LAMP-1 and LAMP-2A were significantly increased, while the levels of α-syn-GFP (the product of the transgene) were significantly decreased by DHM and Sal B treatments. However, the levels of mouse endogenous α-syn were not significantly different among the groups. Significant differences are indicated as DHM (c) and Sal B (d) treatments in the CS and SNpc compared with the saline treated group. All data shown are representative of at least three independent experiments (mean ± SD, *p<0.05, **p<0.01)

DHM and Sal B treatment lead to decreased astrogliosis and microgliosis in vivo

To investigate the effects of DHM and Sal B on inflammatory responses in the CS and SNpc, we examined the density and quantity of activated Iba1- and GFAP- positive cells in the substantia nigra and the striatum after DHM and Sal B treatments in BAC-α-syn-GFP transgenic mice. We observed a reduction in astrogliosis and microgliosis in both the CS and SNpc (Fig. 8a, b) by quantifying the number of activated astroglial cells and microglial cells as well as the astroglial and microglial density of IF staining results in BAC-α-syn-GFP transgenic mice (Fig. 8c, d). Quantification of the Iba1 (Fig. 8e, f) and GFAP (Fig. 8g, h) signal intensity of IHC staining also revealed a deactivation of astroglia and microglia by DHM and Sal B treatments in the CS as well as in the SNpc. These data suggest that DHM and Sal B treatments have anti-neuroinflammatory effects in BAC-α-syn-GFP transgenic mice.
Fig. 8

Activation of microglia and astrocytes in transgenic mice after DHM and Sal B treatments. Alterations in cell numbers of microglia are concomitant to that of astrocytes (a and b). Representative images of the microglial marker Iba1 (a) and the astroglial marker GFAP (b) in the CS and SNpc of BAC-α-syn-GFP transgenic mice treated with DHM/Sal B or saline control (8 animals/group, male). Quantification of activated cell numbers and density of the microglial marker Iba1 (c) and the astroglial marker GFAP (d) in the CS and SNpc of BAC-α-syn-GFP transgenic mice are displayed with treatments of DHM/Sal B or saline control. IHC assessment of astrogliosis paralleled by microgliosis in transgenic mice after DHM and Sal B treatments (e-h). Representative images of Iba1+ microglia (e) and GFAP+ astroglia (g) in the CS and SNpc of BAC-α-syn-GFP transgenic mice treated with DHM and Sal B or saline. Effects of DHM and Sal B treatments in the CS and SNpc of BAC-α-syn-GFP transgenic mice compared to saline treatment are represented by quantification of optical density of the microglial marker Iba1 (f) and the astroglial marker GFAP (h) in each individual group. All values are mean + S.E.M, differences are significant at *p<0.05, **p < 0.01. Scare bar = 50 μm

Discussion

In this study, we have shown that DHM and Sal B induce the degradation of α-syn aggregates and we attribute this to the observed activation of the CMA pathway both in vitro and in vivo. Firstly, low doses of DHM and Sal B could reduce the expression level of α-syn aggregates by up-regulating the CMA pathway in the SynT-aggregation cell model. We then confirmed that DHM and Sal B up-regulate LAMP-1, an important marker for the structure and function of lysosomal membranes and LAMP-2A, a key marker of CMA, in α-syn transgenic mice and decrease astrogliosis and microgliosis. This data indicates that treatment with DHM or Sal B upregulates the CMA pathway, which is known to play a key role in degrading abnormal a-syn aggregates.

Autophagy has been considered an essential mechanism in neurodegenerative diseases such as PD and Alzheimer’s disease [39, 40, 41]. Increasing evidence suggests that aggregated and misfolded α-syn drives the pathology of PD. Although it has been reported that Sal B can inhibit Aβ aggregation in cultured cells [24, 42], no evidence exists to indicate whether DHM or SalB have a regulatory effect on α-syn aggregation. Here, we observed decreased α-syn expression in cell models after DHM and Sal B treatments, as well as decreased levels of the α-syn protein in α-syn transgenic mice. Therefore, it is possible that the degradation pathway of aggregated α-syn may be directly targeted by DHM and Sal B. From a structural chemistry point of view, several studies have provided evidence that compounds which have three adjacent dihydroxy groups (e.g. DHM) or vicinal dihydroxy groups (e.g. Sal B) are effective inhibitors of α-syn oligomerization and fibrilization [43, 44, 45]. Thus, the special structures of DHM and Sal B may have a direct inhibitory effect on the aggregation of α-syn.

Lysosomes are the primary compartment for the degradation of intracellular proteins via autophagy [46]. The existence of abnormal intracellular α-syn-positive aggregates in PD indicates that the degradation capability of lysosomes may be impaired [3, 47]. CMA exerts a protective function by selectively targeting damaged or misfolded proteins for lysosomal degradation. Dysfunction of CMA in PD is characterized by reduced expression of the membrane receptor of CMA, lysosomal-associated membrane protein (LAMP) [4, 48, 49]. Several studies using different cell culture models of synucleinopathies have shown that the CMA pathway participates in α-syn degradation and its alteration may support α-syn mediated neurodegeneration [3, 7, 50]. Most of the previous studies report increased accumulation of α-syn by inhibiting CMA pathway, or reduced α-syn levels by activating CMA pathway [39, 51]. LAMP-2A plays an important role in the CMA pathway of α-syn degradation and an increased expression of LAMP-2A can activate the CMA pathway [4, 13, 52]. Here, we observed a reduction of α-syn aggregation by DHM and Sal B in vitro. The aggregation cell model is characterized by ThS-positive α-syn aggregates, because the dye can specifically bind to amyloid-like structures to indicate the formation of large inclusions [36, 53]. Smaller α-syn positive aggregates generated by untagged α-syn are also found in cell models, but are not positive for ThS. Thus, our data suggest that DHM and Sal B not only enhance α-syn degradation by the CMA pathway, but also modulate α-syn aggregation. Rapamycin has been widely used to inhibit the mTOR pathway and thereby induce autophagy [54]. Chloroquine blocks lysosomal function by raising lysosomal pH, thereby inhibiting lysosomal function [55]. Here, blocking autophagy with CQ resulted in SynT aggregation and increased toxicity. However, ALP modulation by rapamycin did not increase the toxicity of SynT and α-syn aggregation was reduced. We can see a clear effect of DHM and Sal B treatment on LAMP-1 and LAMP-2A levels, and a similar effect on aggregation induced by rapamycin. Notably, we observed that both LAMP-1 and LAMP-2A clearly co-localized with α-syn in transgenic mice after administration of DHM and Sal B, which is in agreement with previous findings [48, 56]. Recent studies showed that DHM and Sal B can enhance the level of autophagy by regulating the mTOR pathway [31, 57]. Sal B can stabilize the lysosome membrane by increasing the LAMP-1 protein level by reducing lysosomal enzyme translocation to the cytosol [58]. Levels of LAMP-1 can be increased through the regulation of the nuclear localization of Transcription factor EB (TFEB) via the mTOR signaling pathway [59]. LAMP-2A and the mTOR complex were highly relevant in vivo [60]. Thus, we reasoned that DHM and Sal B may enhance the degradation of α-syn by up-regulating the level of CMA and enhancing the expression of LAMP-1 and LAMP-2A via the mTOR signaling pathway.

As previously reported, DHM exerts a more rapid effect in association with enhancement of brain-derived neurotrophic factor expression and inhibition of neuroinflammation [61]. Administration of Sal B significantly decreased microglial activation in the central nervous system [62], promoted autophagy and induced the clearance of inflammasome, resulting in neuroprotective actions [63]. In our study, we demonstrated that both DHM and Sal B treatments effectively inhibited astroglia- and microglia-mediated neuroinflammation. It appears that DHM and Sal B can penetrate the blood-brain barrier and display multiple pharmacological activities, including oxidation resistance, anti-tumor properties and neuroprotection [23, 64], indicating potential for clinical application [65]. Both DHM and Sal B displayed a protective role towards dopaminergic neurons by exerting neuroprotective effects [66, 67].

Conclusions

Through small molecule screening, we have identified two small molecules, DHM and Sal B that can inhibit α-synuclein aggregation in cell-free conditions. In α-synuclein overexpressing cell and animal models, we have demonstrated that both DHM and Sal B can inhibit α-synuclein accumulation and aggregation in cells and mouse brains. Decreasing α-synuclein aggregates concomitantly activates CMA pathways by increasing expression of LAMP-2A and macroautophagy by increasing LC3-II and LAMP-1, and is accompanied by the inhibition of microglial activation and neuroinflammation. Our results show that DHM and Sal B are effective in modulating α-synuclein accumulation and aggregate formation and augment CMA and macroautophagy. Furthermore, many chemotherapeutic agents have been reported to induce CMA activation, suggesting that autophagic protein degradation could be a potential approach to prevent and treat synucleinopathies. Our study strongly suggests that these two compounds may represent a detoxification and anti-inflammatory mechanism which could be targeted for clinical interventions of PD caused by abnormal accumulation and aggregation of α-syn.

Notes

Acknowledgements

We thank Dr. Andrew McCourt for linguistic editing.

Authors' contributions

JYL conceived and coordinated the study. WJZ and JYL designed the experiments and wrote the paper. All authors reviewed and contributed to the writing. WJZ performed in vitro and in vivo (with old animals) experiments, analyzed and interpreted the data. MA, NNV, AS and OMWA performed the cell-free screening of the compounds. CH, MD and WL performed in vivo experiments (with young animals). ZYW provided intellectual input. TFO provided reagents for in vitro experiments. All authors read and approved the final manuscript.

Funding

We would like to acknowledge financial supports by the National Natural Science Foundation (81430025, 81701265, 31800898, U801681). Acknowledgements are also to the supports of the Swedish Research Council (K2015-61X-22297-03-4), EU-JPND (aSynProtec) and EU-JPND (REfrAME), EU H2020-MSCA-ITN-2016 (Syndegen), BAGADILICO-Excellence in Parkinson and Huntington Research, the Strong Research Environment MultiPark (Multidisciplinary research on Parkinson’s disease), the Swedish Parkinson Foundation (Parkinsonfonden), Torsten Söderbergs Foundation, Olle Engkvist Byggmästere Foundation. W.L. is supported by a scholarship from the China Scholarship Council. TFO is supported by the DFG Center for Nanoscaly Microscopy and Molecular Physiology of the Brain (CNMPB).

Ethics approval and consent to participate

All animal experiments followed the Institutional Animal Care and all procedures were performed under the specifications set by the Ethical Committee for Use of laboratory animals at Lund University, Sweden and at Northeastern University, China.

Consent for publication

All the authors have approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Supplementary material

40035_2019_159_MOESM1_ESM.tif (2.2 mb)
Additional file 1: SynT-aggregation model and WT α-syn control. A 93 aa long C-terminal tag fused to α-syn (SynT) (Ai) and synphilin-1 were transiently co-transfected to H4 cells and resulted in larger intracellular α-syn inclusions. Immunostaining for α-syn revealed large inclusions that were ThS-positive (Bi, Bii). Smaller aggregates were ThS-negative (Bi, Bii). Transfection with untagged human WT α-syn (WT α-Syn) (Aii) did not result in larger α-syn immunopositive inclusions (Ci, Cii). (TIF 2251 kb)
40035_2019_159_MOESM2_ESM.tif (1.6 mb)
Additional file 2: Expression of LC3-II and LAMP-2A in α-syn transfected H4 cells in response to treatments with DHM, Sal B and 3-MA. A control group with wildtype α-syn plasmid transfection was performed as ‘WT α-syn’. SynT and synphilin 1 co-transfection was performed as the experimental group with DHM, Sal B, and 3-MA treatments. (A) The levels of SynT, LC3-II and LAMP-1/-2A were measured by Western blots. Quantitative analyses of α-syn (SynT), LC3-II and LAMP-1/-2A normalized to β-actin (B-E) (n = 5). (B) SynT levels were increased even after treatment with 3-MA in DHM or Sal B treated groups. (C) 3-MA led to a decrease in LC3-II levels in SynT transfected H4 cells and the level of LC3-II was recovered after treating with DHM or Sal B. (D-E) LAMP-1 and LAMP-2A expression levels were increased in DHM or Sal B treated cells as compared to the 3-MA-treated SynT cells. * shows the comparison between SynT/P and DHM/3-MA and Sal B/3-MA, while # shows the comparison between 3-MA and DHM/3-MA and Sal B/3-MA. All data shown are representative of at least three independent experiments (mean ± SD, *p<0.01, #p<0.01). (TIF 1633 kb)
40035_2019_159_MOESM3_ESM.tif (1.6 mb)
Additional file 3: Open field tests showing the locomotor function of 6 and 9 month old mice after DHM and Sal B treatments. Ambulatory movement for (A) 6 month old and (B) 9 month old WT (wt), or homozygous (tg/tg) mice (8 animals/group, male), recorded for 15 min each. Two groups of homozygous (tg/tg) mice (8 animals/group, male) received intraperitoneal administrations of 5 mg/kg DHM/Sal B. (TIF 1594 kb)
40035_2019_159_MOESM4_ESM.tif (5.5 mb)
Additional file 4: α-Syn-GFP co-localizes with CMA markers in transgenic mice. α-Syn was expressed with GFP (green) and subjected to immunocytochemistry for LAMP-1 and LAMP-2A (red) followed by confocal microscopic analyses. In the presence of overexpressed α-syn-GFP, a greater quantity of LAMP-1 and LAMP-2A co-localize with α-syn in the DHM and Sal B treated group compared to the saline treated group in the SNpc of BAC-α-syn-GFP transgenic mice (8 animals/group, male). White arrows point to lysosomes where α-syn-GFP and LAMP-1/-2A are co-localized. Scale bar = 50 μm. (TIF 5592 kb)

References

  1. 1.
    Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, et al. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol. 2006;111(2):101–8.CrossRefGoogle Scholar
  2. 2.
    Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.CrossRefGoogle Scholar
  3. 3.
    Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–5.CrossRefGoogle Scholar
  4. 4.
    Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. Journal of Biological Chemistry. 2008;283(35):23542–56.CrossRefGoogle Scholar
  5. 5.
    Dice JF. Chaperone-mediated autophagy. Autophagy. 2007;3(4):295–9.CrossRefGoogle Scholar
  6. 6.
    Yang RX, Gao GD, Mao ZX, Yang Q. Chaperone-Mediated Autophagy and Mitochondrial Homeostasis in Parkinson's Disease. Parkinsons Dis-Us; 2016.Google Scholar
  7. 7.
    Auluck PK, Chan HYE, Trojanowski JQ, Lee VMY, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002;295(5556):865–8.CrossRefGoogle Scholar
  8. 8.
    Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. Journal of Biological Chemistry. 2004;279(24):25497–502.CrossRefGoogle Scholar
  9. 9.
    Andrejewski N, Punnonen EL, Guhde G, Tanaka Y, Lullmann-Rauch R, Hartmann D, et al. Normal lysosomal morphology and function in LAMP-1-deficient mice. J Biol Chem. 1999;274(18):12692–701.CrossRefGoogle Scholar
  10. 10.
    Eskelinen EL, Schmidt CK, Neu S, Willenborg M, Fuertes G, Salvador N, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol Biol Cell. 2004;15(7):3132–45.CrossRefGoogle Scholar
  11. 11.
    Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, et al. Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy. Science. 2009;323(5910):124–7.CrossRefGoogle Scholar
  12. 12.
    Rout AK, Strub MP, Piszczek G, Tjandra N. Structure of Transmembrane Domain of Lysosome-associated Membrane Protein Type 2a (LAMP-2A) Reveals Key Features for Substrate Specificity in Chaperone-mediated Autophagy. Journal of Biological Chemistry. 2014;289(51):35111–23.CrossRefGoogle Scholar
  13. 13.
    Murphy KE, Gysbers AM, Abbott SK, Spiro AS, Furuta A, Cooper A, et al. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease. Movement Disorders. 2015;30(12):1639–47.CrossRefGoogle Scholar
  14. 14.
    Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. Faseb J. 2006;20(12):2050–7.CrossRefGoogle Scholar
  15. 15.
    Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780–6.CrossRefGoogle Scholar
  16. 16.
    Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302(5646):819–22.CrossRefGoogle Scholar
  17. 17.
    Ebrahimi-Fakhari D, Unni VK, Rockenstein E, Masliah E, Hyman BT, McLean PJ. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. Movement Disorders. 2011;26:S15–S6.Google Scholar
  18. 18.
    Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, et al. alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. Journal of Cell Biology. 2010;190(6):1023–37.CrossRefGoogle Scholar
  19. 19.
    Baek KH, Park J, Shin I. Autophagy-regulating small molecules and their therapeutic applications. Chem Soc Rev. 2012;41(8):3245–63.CrossRefGoogle Scholar
  20. 20.
    Zhuang P, Zhang Y, Cui G, Bian Y, Zhang M, Zhang J, et al. Direct Stimulation of Adult Neural Stem/Progenitor Cells In Vitro and Neurogenesis In Vivo by Salvianolic Acid B. Plos One. 2012;7(4).CrossRefGoogle Scholar
  21. 21.
    Ardah MT, Paleologou KE, Lv GH, Menon SA, Abul Khair SB, Lu JH, et al. Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiology of Disease. 2015;74:89–101.CrossRefGoogle Scholar
  22. 22.
    Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294(5545):1346–9.CrossRefGoogle Scholar
  23. 23.
    Chen T, Liu W, Chao X, Zhang L, Qu Y, Huo J, et al. Salvianolic acid B attenuates brain damage and inflammation after traumatic brain injury in mice. Brain Research Bulletin. 2011;84(2):163–8.CrossRefGoogle Scholar
  24. 24.
    Durairajan SSK, Yuan Q, Xie L, Chan W-S, Kum W-F, Koo I, et al. Salvianolic acid B inhibits A beta fibril formation and disaggregates preformed fibrils and protects against A beta-induced cytotoxicty. Neurochemistry International. 2008;52(4-5):741–50.CrossRefGoogle Scholar
  25. 25.
    Liu B, Du J, Zeng J, Chen C, Niu S. Characterization and antioxidant activity of dihydromyricetin-lecithin complex. European Food Research and Technology. 2009;230(2):325–31.CrossRefGoogle Scholar
  26. 26.
    Jiang B, Le L, Pan H, Hu K, Xu L, Xiao P. Dihydromyricetin ameliorates the oxidative stress response induced by methylglyoxal via the AMPK/GLUT4 signaling pathway in PC12 cells. Brain Research Bulletin. 2014;109:117–26.CrossRefGoogle Scholar
  27. 27.
    Hou X, Tong Q, Wang W, Xiong W, Shi C, Fang J. Dihydromyricetin protects endothelial cells from hydrogen peroxide-induced oxidative stress damage by regulating mitochondrial pathways. Life Sciences. 2015;130:38–46.CrossRefGoogle Scholar
  28. 28.
    Wu S, Liu B, Zhang Q, Liu J, Zhou W, Wang C, et al. Dihydromyricetin Reduced Bcl-2 Expression via p53 in Human Hepatoma HepG2 Cells. Plos One. 2013;8(11).CrossRefGoogle Scholar
  29. 29.
    Shi LY, Zhang T, Liang XY, Hu Q, Huang J, Zhou Y, et al. Dihydromyricetin improves skeletal muscle insulin resistance by inducing autophagy via the AMPK signaling pathway. Molecular and Cellular Endocrinology. 2015;409(C):92–102.CrossRefGoogle Scholar
  30. 30.
    Shi LY, Zhang T, Zhou Y, Zeng XL, Ran L, Zhang QY, et al. Dihydromyricetin improves skeletal muscle insulin sensitivity by inducing autophagy via the AMPK-PGC-1 alpha-Sirt3 signaling pathway. Endocrine. 2015;50(2):378–89.CrossRefGoogle Scholar
  31. 31.
    Xia J, Guo S, Fang T, Feng D, Zhang X, Zhang Q, et al. Dihydromyricetin induces autophagy in HepG2 cells involved in inhibition of mTOR and regulating its upstream pathways. Food and Chemical Toxicology. 2014;66:7–13.CrossRefGoogle Scholar
  32. 32.
    Du GH, Qiu Y, Zhang JT. Salvianolic acid B protects the memory functions against transient cerebral ischemia in mice. Journal of Asian Natural Products Research. 2000;2(2):145–52.CrossRefGoogle Scholar
  33. 33.
    Hao YB, Xie TP, Korotcov A, Zhou YF, Pang XW, Shan L, et al. Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways. Int J Cancer. 2009;124(9):2200–9.CrossRefGoogle Scholar
  34. 34.
    Hansen C, Bjorklund T, Petit GH, Lundblad M, Murmu RP, Brundin P, et al. A novel alpha-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of alpha-synuclein-GFP. Neurobiology of Disease. 2013;56:145–56.CrossRefGoogle Scholar
  35. 35.
    Poehler A-M, Xiang W, Spitzer P, May VEL, Meixner H, Rockenstein E, et al. Autophagy modulates SNCA/alpha-synuclein release, thereby generating a hostile microenvironment. Autophagy. 2014;10(12):2171–92.CrossRefGoogle Scholar
  36. 36.
    Lazaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, et al. Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. Plos Genet. 2014;10(11).CrossRefGoogle Scholar
  37. 37.
    Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. alpha-synuclein is degraded by both autophagy and the proteasome. Journal of Biological Chemistry. 2003;278(27):25009–13.CrossRefGoogle Scholar
  38. 38.
    Pivtoraiko VN, Harrington AJ, Mader BJ, Luker AM, Caldwell GA, Caldwell KA, et al. Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction. Journal of Neurochemistry. 2010;114(4):1193–204.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Xilouri M, Vogiatzi T, Vekrellis K, Stefanis L. alpha-synuclein degradation by autophagic pathways - A potential key to Parkinson's disease pathogenesis. Autophagy. 2008;4(7):917–9.CrossRefGoogle Scholar
  40. 40.
    Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441(7095):880–4.CrossRefGoogle Scholar
  41. 41.
    Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441(7095):885–9.CrossRefGoogle Scholar
  42. 42.
    Lin YH, Liu AH, Wu HL, Westenbroek C, Song QL, Yu HM, et al. Salvianolic acid B, an antioxidant from Salvia miltiorrhiza, prevents Abeta (25-35)-induced reduction in BPRP in PC12 cells. Biochem Biophys Res Commun. 2006;348(2):593–9.CrossRefGoogle Scholar
  43. 43.
    Caruana M, Hogen T, Levin J, Hillmer A, Giese A, Vassallo N. Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. Febs Lett. 2011;585(8):1113–20.CrossRefGoogle Scholar
  44. 44.
    Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Journal of Neurochemistry. 2006;97(1):105–15.CrossRefGoogle Scholar
  45. 45.
    Rao JN, Dua V, Ulmer TS. Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry-Us. 2008;47(16):4651–6.CrossRefGoogle Scholar
  46. 46.
    Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Bio. 2009;10(9):623–35.CrossRefGoogle Scholar
  47. 47.
    Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. Journal of Clinical Investigation. 2008;118(2):777–88.PubMedGoogle Scholar
  48. 48.
    Cai ZL, Shi JJ, Yang YP, Cao BY, Wang F, Huang JZ, et al. MPP+ impairs autophagic clearance of alpha-synuclein by impairing the activity of dynein. Neuroreport. 2009;20(6):569–73.CrossRefGoogle Scholar
  49. 49.
    Malkus KA, Ischiropoulos H. Regional deficiencies in chaperone-mediated autophagy underlie alpha-synuclein aggregation and neurodegeneration. Neurobiology of Disease. 2012;46(3):732–44.CrossRefGoogle Scholar
  50. 50.
    Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Research. 2014;24(1):92–104.CrossRefGoogle Scholar
  51. 51.
    Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant alpha-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy. Plos One. 2009;4(5).CrossRefGoogle Scholar
  52. 52.
    Crabtree D, Boyer-Guittaut M, Ouyang X, Fineberg N, Zhang J. Dopamine and its metabolites in cathepsin D heterozygous mice before and after MPTP administration. Neuroscience Letters. 2013;538:3–8.CrossRefGoogle Scholar
  53. 53.
    Kawamata H, McLean PJ, Sharma N, Hyman BT. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. Journal of Neurochemistry. 2001;77(3):929–34.CrossRefGoogle Scholar
  54. 54.
    Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007;6(4):304–12.CrossRefGoogle Scholar
  55. 55.
    Shao E, Forgac M. Involvement of the nonhomologous region of subunit A of the yeast V-ATPase in coupling and in vivo dissociation. Journal of Biological Chemistry. 2004;279(47):48663–70.CrossRefGoogle Scholar
  56. 56.
    Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Human Molecular Genetics. 2014;23(15):3943–57.CrossRefGoogle Scholar
  57. 57.
    Gong L, Di C, Xia X, Wang J, Chen G, Shi J, et al. AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells. Int J Oncol. 2016;49(6):2538–48.CrossRefGoogle Scholar
  58. 58.
    Yan XF, Zhao P, Ma DY, Jiang YL, Luo JJ, Liu L, et al. Salvianolic acid B protects hepatocytes from H2O2 injury by stabilizing the lysosomal membrane. World J Gastroenterol. 2017;23(29):5333–44.CrossRefGoogle Scholar
  59. 59.
    Bai LJ, Mei XF, Wang YF, Yuan YJ, Bi YL, Li G, et al. The Role of Netrin-1 in Improving Functional Recovery through Autophagy Stimulation Following Spinal Cord Injury in Rats. Front Cell Neurosci. 2017;11.Google Scholar
  60. 60.
    Hodson N, McGlory C, Oikawa SY, Jeromson S, Song Z, Ruegg MA, et al. Differential localization and anabolic responsiveness of mTOR complexes in human skeletal muscle in response to feeding and exercise. Am J Physiol Cell Physiol. 2017;313(6):C604–C11.CrossRefGoogle Scholar
  61. 61.
    Ren Z, Yan P, Zhu L, Yang H, Zhao Y, Kirby BP, et al. Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation. Psychopharmacology (Berl). 2017.Google Scholar
  62. 62.
    Zhang JQ, Wu XH, Feng Y, Xie XF, Fan YH, Yan S, et al. Salvianolic acid B ameliorates depressive-like behaviors in chronic mild stress-treated mice: involvement of the neuroinflammatory pathway. Acta Pharmacol Sin. 2016;37(9):1141–53.CrossRefGoogle Scholar
  63. 63.
    Jiang P, Guo Y, Dang R, Yang M, Liao D, Li H, et al. Salvianolic acid B protects against lipopolysaccharide-induced behavioral deficits and neuroinflammatory response: involvement of autophagy and NLRP3 inflammasome. J Neuroinflammation. 2017;14(1):239.CrossRefGoogle Scholar
  64. 64.
    Liang J, Lindemeyer AK, Shen Y, Lopez-Valdes HE, Martinez-Coria H, Shao XSM, et al. Dihydromyricetin Ameliorates Behavioral Deficits and Reverses Neuropathology of Transgenic Mouse Models of Alzheimer's Disease. Neurochemical Research. 2014;39(6):1171–81.CrossRefGoogle Scholar
  65. 65.
    Grossi C, Guccione C, Isacchi B, Bergonzi MC, Luccarini I, Casamenti F, et al. Development of Blood-Brain Barrier Permeable Nanoparticles as Potential Carriers for Salvianolic Acid B to CNS. Planta Med. 2017;83(5):382–91.PubMedGoogle Scholar
  66. 66.
    Ren ZX, Zhao YF, Cao T, Zhen XC. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacologica Sinica. 2016;37(10):1315–24.CrossRefGoogle Scholar
  67. 67.
    Zhou J, Qu XD, Li ZY, Wei-Ji LQ, Ma YH, et al. Salvianolic Acid B Attenuates Toxin-Induced Neuronal Damage via Nrf2-Dependent Glial Cells-Mediated Protective Activity in Parkinson's Disease Models. Plos One. 2014;9(7).CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Jia-Zhen Wu
    • 1
    • 6
  • Mustafa Ardah
    • 2
  • Caroline Haikal
    • 3
  • Alexander Svanbergsson
    • 3
  • Meike Diepenbroek
    • 3
  • Nishant N. Vaikath
    • 3
    • 4
  • Wen Li
    • 3
  • Zhan-You Wang
    • 5
  • Tiago F. Outeiro
    • 7
    • 8
  • Omar M. El-Agnaf
    • 4
  • Jia-Yi Li
    • 1
    • 3
    • 5
    Email author
  1. 1.Institute of Neuroscience, College of Life and Health SciencesNortheastern UniversityShenyangChina
  2. 2.Department of Biochemistry, College of Medicine and Health SciencesUnited Arab Emirates UniversityAl-AinUnited Arab Emirates
  3. 3.Neural Plasticity and Repair Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, BMC A10LundSweden
  4. 4.Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education CityQatar FoundationDohaQatar
  5. 5.Institute of Heath SciencesChina Medical UniversityShenyangPeople’s Republic of China
  6. 6.Key Laboratory of Maternal-Fetal Medicine of Liaoning Province and Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning ProvinceShengjing Hospital of China Medical UniversityShenyangChina
  7. 7.Department of Experimental Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, Center for Biostructural Imaging of NeurodegenerationUniversity Medical Center GöttingenGöttingenGermany
  8. 8.Max Planck Institute for Experimental MedicineGöttingenGermany

Personalised recommendations